Preeclampsia diagnosis is critical to the well-being of both mother and baby. It involves the detection of high blood pressure and presence of protein in urine during pregnancy. Left undiagnosed, it can cause serious complications like organ failure leading to maternal or fetal death. Currently, various diagnostic tests like blood and urine tests are available to detect preeclampsia symptoms. The increasing use of biomarker-based tests provide early and non-invasive diagnosis of this potentially life-threatening condition.
The global preeclampsia diagnostics market is estimated to be valued at US$ 1828.84 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Preeclampsia Diagnostics Market Size are The Dow Chemical Company, BASF SE, Covestro A.G., Huntsman Corp., Eastman Chemical Co., Mitsui Chemicals Inc, Recticel S.A., RTP Company Inc., Lubrizol Corp., Rampf Holding GmbH & Co. KG. These major players dominate the global market with their wide distribution channels and diverse product portfolios.
The growing prevalence of high blood pressure disorders during pregnancy presents significant opportunities for market players. According to WHO, over 10% of all maternal deaths globally each year are due to preeclampsia and eclampsia alone, with majority occurring in low and middle income countries.
With increasing global burden of preeclampsia, many companies are expanding their footprint beyond developed regions to emerging markets. Manufacturers are also focusing on development of rapid point-of-care diagnostic tests to enable timely treatment in remote areas with limited healthcare access.
Market Drivers
Rising incidence rates of pregnancy-induced hypertension is a key factor fueling the demand for preeclampsia diagnostic tools. According to NIH, preeclampsia complicates approximately 2-8% of all pregnancies globally each year. In developed countries, it is a leading cause of maternal and fetal morbidity and mortality.
Technological advancements have enabled development of novel diagnostic platforms for early detection. In recent years, several blood and urine biomarker-based tests have been launched which can identify preeclampsia even before the onset of symptoms. This is helping improve health outcomes.
Market Restrains
However, high costs of advanced diagnostic devices especially the newer biomarkers-based tests are a major barrier, limiting widespread adoption in low resource settings. Limited awareness among high-risk population groups in developing nations also poses challenges. Stringent regulatory approval process and long product launch timelines further restraint market growth to some extent.
Key Takeaways summarizes the key points discussed including key players, opportunities present because of disease prevalence and global expansion driven by disease burden. Market drivers explains the growth factors and market restrain mentions the challenges faced by the preeclampsia diagnostics market.
Segment Analysis
The Preeclampsia Diagnostics market has been categorized into Instruments and Consumables on the basis of type of products. The Instruments segment dominates the market as it covers majority of the testing part in preeclampsia diagnosis. Instruments like blood pressure monitoring devices and urine analyzers are commonly used for initial screening of pregnant women suffering from high blood pressure or protein in urine. The consumables segment is expected to witness steady growth during the forecast period owing to rising number of diagnostic tests being performed globally.
Global Analysis
Regionally, North America accounted for the largest revenue share in the global preeclampsia diagnostics market in 2024 owing to developed healthcare infrastructure and high awareness levels about the condition in the US and Canada. The Asia Pacific region is projected to witness fastest growth during the forecast period from 2024 to 2030. Availability of advanced diagnostic technologies at affordable prices and rising healthcare expenditure in countries like China and India are factors contributing to higher demand for preeclampsia diagnostics in Asia Pacific. Additionally, growing number of private players offering point-of-care testing in hospitals and clinics also supports the regional market growth. Countries like Brazil and Mexico are expected to drive the Latin American market for preeclampsia diagnostics due to improving reimbursement scenario and diagnostic lab infrastructure in the region.
Get more insights on- Preeclampsia Diagnostics Market
